The listing below shows our latest News Items and is updated regularly. If you wish to post a news item please select the 'Post News' button on the right. The displayed news feed starts on 1st August 2016. Older items can be found here.
To 'Post Your News' use the button at the top right.
We are pleased to present below all posts archived in 'August, 2018'. If you still can't find what you are looking for, try using the search box.
BOSTON & OXFORD, UK: Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Genomics plc today announced a three-year collaboration, extendable to five years, to use human genetics and machine learning to improve discovery of targets for precision medicines,
Read the rest of entry »
Oxford Genetics has secured a multi-million pound contract with a global ecommerce provider of reagents and tools to the research and clinical community.
Oxford Genetics is a leader in innovative synthetic biology-based technologies for biologics discovery, development and delivery with operations in the UK and US. It has significant expertise in DNA design, virus and protein-based biologics and cell lines, and is working with leading research, diagnostic and therapeutic companies and research institutes. The company’s extensive use of hardware and software automation allows it to develop new and innovative solutions, the latest of which is its mammalian CRISPR cell line engineering platform.
AMSBIO produce a growing range of experimental cell lines, recombinant proteins and screening services to advance the search for new Chimeric Antigen Receptor (CAR T) cell therapies to treat cancers.
For years, the foundations of cancer treatment were surgery, chemotherapy, and radiation therapy. Over the last twenty years, therapeutic drugs that target cancer cells by homing in on specific molecular changes seen primarily in those cells, have also become standard treatments for many cancers. In the last few years - immunotherapies that enlist and strengthen the power of a patient’s immune system to attack tumors have emerged as a new and very promising cancer treatment.
The National Institute for Health and Care Excellence (NICE) provides reimbursement guidance to the National Health Service (NHS) in England and Wales. The NHS is legally obliged to provide funding for medicines and treatments recommended by NICE’s health technology appraisal (HTA) programmes.
Mologic Ltd, a developer of powerful, personalised diagnostics to improve the lives of patients, has recently announced that it has commenced a clinical trial to evaluate the Company’s urine-based diagnostic, HeadsUp, in monitoring pulmonary exacerbation in cystic fibrosis (CF) patients. The study aims to identify five urinary biomarkers associated with the onset of pulmonary exacerbation in adults with CF. It will also validate the use of the novel point-of-care (POC) test for patient’s self-monitoring of their condition.
AMSBIO TUNR kits allows you to precisely tune gene expression from 100% all the way down to complete knockout, model ranges of gene expression reflecting diversity in patient populations and knockdown essential genes where knockout would result in lethality. In addition, a kit is available that allows you to control endogenous gene expression enabling elimination of artifacts from ectopic expression.
The TUNR Flexible Gene Editing System for Endogenous Genes is designed to generate four cell lines or animal models with four different levels of knockdown of your endogenous gene of interest.
The TUNR Targeted Transgenic kit enables you to insert your gene of interest under TUNR control into the AAVS1 locus. AAVS1 is a safe place to integrate transgenes, allowing predictable expression from a locus known not to alter the expression of other genes or have otherwise negative effects on the cell.
The TUNR Plasmid-Delivered Transgenes kit allows you to control the expression of a transgene. Using the kit, y ...
Disease associated chromosomal rearrangements often have break points located within disease causing genes or in their vicinity. The purpose of this study is to characterize a balanced reciprocal translocation in a girl with intellectual disability and seizures by positional cloning and whole genome sequencing. The translocation was identification by G- banding and confirmed by WCP FISH. Fine mapping using BAC clones and whole genome sequencing using Oxford nanopore long read sequencing technology for a 1.46 X coverage of the genome was done. The positional cloning showed split signals with BAC RP11-943 J20. Long read sequencing analysis of chimeric reads carrying parts of chromosomes X and 20 helped to identify the breakpoints to be in intron 2 of ARHGEF9 gene on Xp11.1 and on 20p13 between RASSF2 and SLC23A2 genes. This is the first report of translocation which successfully ...
We report a customized gene panel assay based on multiplex long-PCR followed by third generation sequencing on nanopore technology (MinION), designed to analyze five frequently mutated genes in chronic lymphocytic leukemia (CLL): TP53, NOTCH1, BIRC3, SF3B1 and MYD88. For this purpose, 12 patients were selected according to specific cytogenetic and molecular features significantly associated with their mutational status. In addition, simultaneous analysis of the targets genes was performed by molecular assays or Sanger Sequencing. Data analysis included mapping to the GRCh37 human reference genome, variant calling and annotation, and average sequencing depth/error rate analysis. The sequencing depth resulted on average higher for smaller amplicons, and the final breadth of coverage of the panel was 94.1%. The error rate was about 6% and 2% for insertions/deletions and single nucleotide variants, respectively. Our gene panel allows analysis of the prognostically relevant genes in CLL, with two PCRs per patient. ...
In the latest edition of Oxford Nanpore's newsletter please take a look at an article: Rapid Diagnosis of Lower Respiratory Infection using Nanopore-based Clinical Metagenomics
Lower respiratory tract infections are the leading cause of death from infectious disease worldwide, causing three million deaths in 2016. A wide range of pathogens cause these infections, making quick diagnosis and prescribing decisions a challenge.
Using the MinION, Charalampous et al. developed a pipeline that was capable of removing up to 99.99% of host nucleic acids from the clinical samples, was 96.6% concordant with culture in terms of pathogen detection, and could accurately detect resistance genes within six hours.
Read the workflow
We are delighted to announce our 2018 OBN Award Finalists. This is the 10th anniversary of the OBN Awards, the life sciences industry’s most highly regarded awards event. 2018 was another record breaking year, with award entries up over 40% on 2017.
OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.